SG11202012819YA - Tricyclic compounds - Google Patents
Tricyclic compoundsInfo
- Publication number
- SG11202012819YA SG11202012819YA SG11202012819YA SG11202012819YA SG11202012819YA SG 11202012819Y A SG11202012819Y A SG 11202012819YA SG 11202012819Y A SG11202012819Y A SG 11202012819YA SG 11202012819Y A SG11202012819Y A SG 11202012819YA SG 11202012819Y A SG11202012819Y A SG 11202012819YA
- Authority
- SG
- Singapore
- Prior art keywords
- tricyclic compounds
- tricyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018092542 | 2018-06-25 | ||
| PCT/CN2019/084601 WO2020001152A1 (fr) | 2018-06-25 | 2019-04-26 | Composés tricycliques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012819YA true SG11202012819YA (en) | 2021-01-28 |
Family
ID=68986044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012819YA SG11202012819YA (en) | 2018-06-25 | 2019-04-26 | Tricyclic compounds |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20210179617A1 (fr) |
| EP (1) | EP3814352A4 (fr) |
| JP (1) | JP7168245B2 (fr) |
| KR (1) | KR102600391B1 (fr) |
| CN (2) | CN112513041B (fr) |
| AU (2) | AU2019295983B2 (fr) |
| BR (1) | BR112020026337A2 (fr) |
| CA (1) | CA3104927C (fr) |
| EA (1) | EA202190103A1 (fr) |
| MX (1) | MX2020014111A (fr) |
| PH (1) | PH12020552210A1 (fr) |
| SG (1) | SG11202012819YA (fr) |
| TW (1) | TWI705965B (fr) |
| WO (1) | WO2020001152A1 (fr) |
| ZA (1) | ZA202100237B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020026337A2 (pt) * | 2018-06-25 | 2021-03-30 | Jacobio Pharmaceuticals Co., Ltd. | Compostos tricíclicos |
| WO2022156757A1 (fr) * | 2021-01-22 | 2022-07-28 | Jingrui Biopharma Co., Ltd. | Composés tricycliques en tant qu'agents anticancéreux |
| WO2024099441A1 (fr) * | 2022-11-11 | 2024-05-16 | Jingrui Biopharma (Shandong) Co., Ltd. | Dégradeur de protéine à bromodomaines et domaine extra-terminal (bet) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014082380A1 (fr) | 2012-11-29 | 2014-06-05 | Sunshine Lake Pharma Co., Ltd. | Composés de type noyaux fusionnés utilisables en tant qu'inhibiteurs du virus de l'hépatite c, compositions pharmaceutiques en contenant et leurs utilisations |
| US9675697B2 (en) * | 2013-03-11 | 2017-06-13 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
| PT3087071T (pt) * | 2013-12-24 | 2018-11-29 | Bristol Myers Squibb Co | Compostos tricíclicos como agentes anticancro |
| US10683290B2 (en) * | 2015-05-11 | 2020-06-16 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| ES2770349T3 (es) * | 2015-05-12 | 2020-07-01 | Bristol Myers Squibb Co | Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| JP6855505B2 (ja) * | 2016-01-20 | 2021-04-07 | ニンボー ウェンダ ファーマー テクノロジー エルティーディー． | ブロモドメイン阻害剤としてのカルボリン誘導体 |
| US20190040063A1 (en) | 2016-02-05 | 2019-02-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tricyclic compound for bromodomain-containing protein inhibitor and preparation pharmaceutical composition, and application thereof |
| WO2017197056A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
| WO2019080941A1 (fr) | 2017-10-27 | 2019-05-02 | Jacobio-Beta Pharmaceuticals Co., Ltd. | Nouveaux composés tricycliques |
| BR112020026337A2 (pt) * | 2018-06-25 | 2021-03-30 | Jacobio Pharmaceuticals Co., Ltd. | Compostos tricíclicos |
| WO2020200284A1 (fr) | 2019-04-04 | 2020-10-08 | 上海华汇拓医药科技有限公司 | Procédé de préparation de composé tricyclique et son utilisation dans le domaine de la médecine |
-
2019
- 2019-04-26 BR BR112020026337-0A patent/BR112020026337A2/pt unknown
- 2019-04-26 JP JP2020572516A patent/JP7168245B2/ja active Active
- 2019-04-26 WO PCT/CN2019/084601 patent/WO2020001152A1/fr unknown
- 2019-04-26 EP EP19826294.1A patent/EP3814352A4/fr active Pending
- 2019-04-26 CN CN201980041760.8A patent/CN112513041B/zh active Active
- 2019-04-26 KR KR1020217002239A patent/KR102600391B1/ko active IP Right Grant
- 2019-04-26 SG SG11202012819YA patent/SG11202012819YA/en unknown
- 2019-04-26 MX MX2020014111A patent/MX2020014111A/es unknown
- 2019-04-26 AU AU2019295983A patent/AU2019295983B2/en active Active
- 2019-04-26 CN CN202210507765.9A patent/CN115109061A/zh active Pending
- 2019-04-26 EA EA202190103A patent/EA202190103A1/ru unknown
- 2019-04-26 CA CA3104927A patent/CA3104927C/fr active Active
- 2019-04-30 TW TW108115066A patent/TWI705965B/zh active
-
2020
- 2020-12-17 PH PH12020552210A patent/PH12020552210A1/en unknown
- 2020-12-22 US US17/129,983 patent/US20210179617A1/en active Pending
-
2021
- 2021-01-13 ZA ZA2021/00237A patent/ZA202100237B/en unknown
- 2021-12-20 AU AU2021290208A patent/AU2021290208B2/en active Active
- 2021-12-23 US US17/561,381 patent/US11466005B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3104927A1 (fr) | 2020-01-02 |
| US11466005B2 (en) | 2022-10-11 |
| TW202017928A (zh) | 2020-05-16 |
| CN112513041B (zh) | 2022-05-10 |
| US20210179617A1 (en) | 2021-06-17 |
| JP7168245B2 (ja) | 2022-11-09 |
| EP3814352A4 (fr) | 2022-03-30 |
| AU2021290208B2 (en) | 2023-09-21 |
| EP3814352A1 (fr) | 2021-05-05 |
| US20220119390A1 (en) | 2022-04-21 |
| KR20210045981A (ko) | 2021-04-27 |
| KR102600391B1 (ko) | 2023-11-10 |
| CA3104927C (fr) | 2023-09-12 |
| AU2019295983A1 (en) | 2021-02-11 |
| CN112513041A (zh) | 2021-03-16 |
| MX2020014111A (es) | 2021-06-15 |
| BR112020026337A2 (pt) | 2021-03-30 |
| CN115109061A (zh) | 2022-09-27 |
| WO2020001152A1 (fr) | 2020-01-02 |
| TWI705965B (zh) | 2020-10-01 |
| AU2021290208A1 (en) | 2022-01-20 |
| ZA202100237B (en) | 2022-10-26 |
| EA202190103A1 (ru) | 2021-03-29 |
| PH12020552210A1 (en) | 2021-06-28 |
| JP2021530455A (ja) | 2021-11-11 |
| AU2019295983B2 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202207722B (en) | Substituted tricyclic compounds | |
| ZA202206253B (en) | Substituted tricyclic compounds | |
| GB201805174D0 (en) | Compounds | |
| GB201810092D0 (en) | Compounds | |
| GB201801355D0 (en) | Compounds | |
| GB201807924D0 (en) | Compounds | |
| GB201810581D0 (en) | Compounds | |
| ZA202100237B (en) | Tricyclic compounds | |
| IL282366A (en) | Tricyclic pesticidal compounds | |
| GB201814151D0 (en) | Compounds | |
| GB201808093D0 (en) | Compounds | |
| SI3810633T1 (sl) | Spojine | |
| GB201809102D0 (en) | Compounds | |
| GB201817083D0 (en) | Compounds | |
| GB201812382D0 (en) | Compounds | |
| GB201810071D0 (en) | Compounds | |
| IL287813A (en) | tricyclic compounds | |
| GB201803340D0 (en) | Compounds | |
| GB201814167D0 (en) | Compounds | |
| GB201801130D0 (en) | Compounds | |
| GB201801128D0 (en) | Compounds | |
| HUP1800332A1 (hu) | Triciklusos vegyületek II | |
| HUP1700522A1 (hu) | Triciklusos vegyületek | |
| GB201817342D0 (en) | Compounds | |
| GB201817291D0 (en) | Compounds |